Plasma Cell Myeloma clinical trials

Explore recruiting plasma cell myeloma clinical trials.

Recruiting plasma cell myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Plasma Cell Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 randomized, open-label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma

Denmark, Germany, Hungary, Greece, Norway, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma

Spain, Italy, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

Sweden, Belgium, Austria, France, Czechia, Greece +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM)

France, Italy, Germany, Poland, Czechia, Hungary +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

International, multi-center, open-label, treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab-based therapy following completion of a Phase 1, 2, or 3 parental study

Italy, Sweden, Finland, Greece, Spain, Czechia +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple Myeloma

Netherlands, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Plasma Cell Myeloma trials by city

Plasma Cell Myeloma in Toronto Plasma Cell Myeloma in Vancouver Plasma Cell Myeloma in Montreal Plasma Cell Myeloma in Calgary Plasma Cell Myeloma in Edmonton Plasma Cell Myeloma in Ottawa Plasma Cell Myeloma in Winnipeg Plasma Cell Myeloma in Quebec City Plasma Cell Myeloma in Hamilton Plasma Cell Myeloma in Kitchener Plasma Cell Myeloma in London Plasma Cell Myeloma in Halifax Plasma Cell Myeloma in New York Plasma Cell Myeloma in Los Angeles Plasma Cell Myeloma in Chicago Plasma Cell Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease